Acrocell Established a Platform for Channelopathies to Accelerate Pharmacology Study

Acrocell Established a Platform for Channelopathies to Accelerate Pharmacology Study

September 03
18:33 2020
Acrocell has established a comprehensive cell bank with a variety of specialized and unique stable cell lines expression ion channels that can be applied to a variety of in vitro research and in vivo pharmacology study instantly. Recently, it announced the release of the professional platform for Channelopathies.

New York, USA – September 3, 2020 – Acrocell, the division of Creative Bioarray, is a biotechnology company with strong strength in the field of electrophysiological techniques. Acrocell has established a comprehensive cell bank with a variety of specialized and unique stable cell lines expression ion channels that can be applied to a variety of in vitro research and in vivo pharmacology study instantly. Recently, it announced the release of the professional platform for Channelopathies.

Channel diseases are a group of newly described neurological diseases combined with defects in ion channel function determined by genetic methods. These diseases are characterized by prominent genetic and phenotypic heterogeneity, which makes them difficult to understand and confusing. This systematic review attempts to classify these diseases according to their main clinical manifestations (ie, myotonia, muscle weakness, migraine, ataxia, epilepsy, and movement disorders) based on the currently recognized molecular basis of clinical syndromes, highlighting areas where genetics and phenotypes overlap.

In the human genome, there are more than 400 genes encoding ion channels, which are transmembrane proteins that mediate ion flux across the membrane. They are expressed in all cell types and participate in almost all physiological processes, including sensory, neurotransmission, muscle contraction, secretion, immune response, cell proliferation and differentiation. Due to the extensive tissue distribution and physiological functions of ion channels, mutations in genes encoding ion channel subunits or their interacting proteins are the cause of inherited ion channel diseases. These diseases range from common to very rare diseases, and their severity may be mild, disabling or life-threatening.

Acrocell summarized the treatment and management of major ion channel diseases of the central and peripheral nervous system, heart, kidney, bone, skeletal muscle and pancreas caused by mutations in calcium, sodium, potassium and chloride ion channels. For most passage diseases, the therapy is mainly empirical and symptomatic treatment, which is usually limited due to lack of efficacy and tolerance to a large number of patients. Other channel diseases can use drugs that target ion channels, such as commercially available sodium channel blockers. Therefore, new and more specific treatment methods need to be developed.

A major advance in the drug treatment of channel diseases is the discovery that ion channel mutations can cause biophysical changes, which can specifically change the sensitivity to drugs. And it has opened the way for pharmacogenetics strategies, enabling the development of personalized therapies with higher efficacy and lower side effects.

“The identification of disease modifiers in ion channel diseases appears to be a new drug-targetable alternative strategy,” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “Acroscell is always devoted to providing researchers and pharmaceutical developers with essential technical information and solutions for your drug discovery and development processes.”

About Acrocell

As a mature division of Creative Bioarray, Acroscell definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.

Media Contact
Company Name: Creative Bioarray
Contact Person: Hannah Cole
Email: Send Email
Phone: 1-631-619-7922
Country: United States
Website: https://www.creative-bioarray.com/acroscell/platform/channelopathies.html